Using anti-hIAPP to protect pancreatic function in Type 2 Diabetes
Anti-hIAPP for the preservation of pancreatic function in Type 2 Diabetes
This study is looking at how a treatment called anti-hIAPP can help protect the pancreas and improve insulin production for people with Type 2 Diabetes by targeting harmful proteins that can damage insulin-producing cells.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Celdara Medical, LLC NIH-funded |
| Lab location | 1 site (Lebanon, United States) |
| Project ID | NIH-10925232 on NIH RePORTER |
What this research studies
This research investigates the role of anti-hIAPP in preserving pancreatic function for individuals with Type 2 Diabetes (T2D). It focuses on the toxic effects of misfolded human islet amyloid polypeptide (hIAPP) that can damage insulin-producing beta cells in the pancreas. By targeting these toxic forms of hIAPP, the study aims to improve insulin secretion and overall glycemic control in patients. The approach involves administering anti-hIAPP to potentially halt or reverse the progression of pancreatic dysfunction associated with T2D.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Type 2 Diabetes or those at high risk of developing the condition.
Not a fit: Patients with Type 1 Diabetes or those who do not have issues related to hIAPP may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that help maintain pancreatic function and improve blood sugar control in patients with Type 2 Diabetes.
How similar studies have performed: While the approach of targeting hIAPP is relatively novel, there is emerging evidence suggesting that similar strategies may have shown promise in preliminary studies.
Where this research is happening
Lebanon, United States
- Celdara Medical, LLC — Lebanon, United States (Active)
Researchers
- Principal investigator: Murad, Joana M — Celdara Medical, LLC
- Study coordinator: Murad, Joana M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.